GlobeNewswire

Atea Pharmaceuticals to Present Positive Clinical Data with At-527 for the Treatment of Chronic Hepatitis C in Patients with Cirrhosis at The Liver Meeting ® 2018

Del
  • AT-527 is a novel pan-genotypic purine nucleotide prodrug NS5B polymerase inhibitor 
  • AT-527 shows profound and equivalent pan-genotypic antiviral activity in cirrhotic and non-cirrhotic (NC) hepatitis C virus (HCV) infected patients
  • AT-527 was safe and well tolerated with once-daily (QD) dosing of 550 mg for 7 days
  • Data support Phase 2 clinical development of AT-527             

BOSTON, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the development of next-generation therapeutics for the treatment of hepatitis C and other single stranded RNA viral infections, today announced it will present positive data from its recently completed Phase IB/IIA trial of AT-527 in treatment-naïve HCV-infected patients, including HCV-infected patients with Child-Pugh A (CPA) cirrhosis. The data will be presented on November 10, 2018 at The Liver Meeting® 2018 sponsored by the American Association for the Study of Liver Diseases taking place in San Francisco, California.   

“Despite the introduction of direct acting antiviral therapies in recent years, hepatitis C continues to represent a serious global health burden, particularly among GT-3 infected, cirrhotic and other difficult-to-treat patient populations,” stated Jean-Pierre Sommadossi, PhD, Atea’s Founder, Chairman and Chief Executive Officer.  “We are very excited about the clinical profile of AT-527, which has demonstrated significant antiviral potency in HCV-infected subjects, regardless of genotype or cirrhotic status. Based upon the results from our proof of concept clinical trial, we believe AT-527 may be the backbone of the first drug regimen that allows for 8-week treatment in both cirrhotic and non-cirrhotic patients. We look forward to advancing AT-527 into Phase II development in 2019.”

Poster No. 1002

Title:   AT-527, a purine nucleotide prodrug, exhibits potent pan-genotypic antiviral activity in HCV-infected subjects with cirrhosis

Date/Time:   Saturday, November 10, 2018; 2:00 pm – 7:30 pm PST

Location: Moscone Center North/South Building, Hall C

A summary of the data to be presented shows rapid and potent pan-genotypic antiviral activity in HCV-infected subjects with cirrhosis, as in non-cirrhotic subjects, with a mean HCV reduction of 2.4 log10 IU/mL after a single dose and a mean maximum HCV RNA reduction of 4.6 log10 IU/mL after 7 days of dosing with AT-527 550 mg. Previously reported data also show a mean maximum HCV RNA reduction of 4.4 log10 IU/mL after 7 days of dosing of AT-527 550 mg in NC GT-1b HCV-infected subjects, and a mean reduction of 4.5 log10 IU/mL after 7 days of dosing was achieved in NC GT-3 HCV-infected subjects. No serious adverse events, dose-limiting toxicities or premature discontinuations were observed, and pharmacokinetic data (PK) in cirrhotic subjects was similar to non-cirrhotic subjects. Emax modeling demonstrated that a dose of 550 mg QD will result in maximum viral load reduction.  

About the Trial

The five-part, Phase IB/IIA trial studied single and multiple doses of AT-527 in healthy and HCV-infected subjects. All HCV-infected subjects were treatment-naïve with HCV RNA ≥ 5 log10 IU/mL. The objectives of the study were to assess safety/tolerability, pharmacokinetics (PK) and antiviral activity.

The trial evaluated single oral doses up to 367 mg (400 mg salt form) in healthy subjects (Part A), single doses up to 550 mg (600 mg salt form) in NC GT-1b HCV-infected subjects (Part B) and multiple doses up to 550 mg once-daily (QD) for 7 days in NC GT-1b HCV-infected subjects (Part C). Additional cohorts evaluated 550 mg QD for 7 days in NC GT-3 (Part D) and CPA cirrhotic GT-1b/3 (Part E) HCV-infected subjects. Plasma levels of AT-273, the nucleoside metabolite of the active triphosphate, were measured using LC-MS/MS; HCV RNA was quantified using COBAS® AmpliPrep/TaqMan® HCV Test v2.0 with a limit of quantitation (LOQ) of 15 IU/mL.

About AT-527

AT-527, a proprietary investigational agent discovered at Atea, is the salt form of a purine nucleotide prodrug NS5B polymerase inhibitor. Unique structural modifications of AT-527 result in differentiated pharmacologic and antiviral properties as compared to other anti-HCV nucleotides. AT-511, the free base of AT-527, showed potent antiviral activity in vitro against wild-type clinical isolates with EC95  values less than 80 nM in all HCV genotypes, and demonstrated about 10- to 14-fold more potency than sofosbuvir (SOF) in GT-1 and GT-3 replicons. AT-511 maintained activity against SOF-resistant S282T single and S282T/L159F double variants, with about 50-fold greater potency than SOF.  

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and transplants. According to the World Health Organization, over 70 million people suffer from chronic hepatitis C. Direct-acting antiviral agents (DAAs) have markedly improved the prognosis of many patients infected with the hepatitis C virus and allow the achievement of a cure in 8 – 12 weeks in select patient populations. Further shortening of the treatment duration in those patients and extending it to more difficult-to-treat HCV patient populations continues to be a sought-after goal of the biotech and pharma industry.  Global sales of DAAs for the treatment of HCV infection are expected to exceed $8 billion in 2018.  

About Atea

Atea Pharmaceuticals is a clinical stage biopharmaceutical company engaged in the discovery and development of proprietary and novel therapeutics for the treatment of hepatitis C and other single stranded RNA viral infections. Atea was founded in 2013 by its Chairman and Chief Executive Officer Jean-Pierre Sommadossi, PhD, and is headquartered in Boston, MA.

Contact:

Company:
Andrea J. Corcoran
617-669-4272
corcoran.andrea@ateapharma.com

Investors and Media:
Constantine Davides
Westwicke Partners
Tel: 339-970-2846
constantine.davides@westwicke.com

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

CEO confidence in growth dips dramatically21.1.2019 18:45Pressemelding

Uncertainty in global economic growth in almost all countries, caution prevails US remains key target market for growth with China narrowing the gap, both see a decline from 2018 Trade conflicts, policy uncertainty, geopolitical issues and skills gap impacting strength of global economy and growth DAVOS, Switzerland, Jan. 21, 2019 (GLOBE NEWSWIRE) -- What a difference a year makes. Nearly 30% of business leaders believe that global economic growth will decline in the next 12 months, approximately six times the level of 5% last year – a record jump in pessimism. This is one of the key findings of PwC’s 22nd annual survey of 1,300 plus CEOs around the world, launched today at the World Economic Forum Annual Meeting in Davos. This is in vivid contrast to last year’s record jump, 29% to 57%, in optimism about global economic growth prospects. Although, all is not doom and gloom: 42% still see an improved economic outlook, though this is down significantly from a high of 57% in 2018. Overal

Komet announces initial Mineral Resource Estimate for the Kabaya Prospect, (Dabia Sud property, Mali)21.1.2019 15:10Pressemelding

QUEBEC CITY, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Komet Resources inc. (TSX-V: KMT) (“Komet” or the “Company”) is pleased to report an initial mineral resource estimate for the Kabaya gold prospect drill prospect, located in the southern part of its Dabia Sud exploration permit (“the Property”) in Western Mali, West Africa. Highlights of the Resource Estimate include : An Indicated Resource of 3.17 million tonnes (Mt) grading 1.03 g/t for 105,000 contained gold ounces and an Inferred Resource of 0.96 Mt grading 1.14 g/t for 35,000 contained gold ounces at a cut-off grade of 0.40 g/t Au (table 1). The pit constrained resource is based on optimized pit shells using a gold price of 1350 US$ and a presumed heap leach gold recovery of saprolite ore. Gold mineralization at Kabaya remains open at depth in bedrock and laterally to the south-west and north-west. Komet intends to continue the resource definition drilling program in order to further develop the resource laterally in saprolite and at

INVNT Expands Global Footprint With Singapore Launch21.1.2019 15:07Pressemelding

NEW YORK, NY, Jan. 21, 2019 (GLOBE NEWSWIRE) -- INVNT, the global live brand storytelling agency™, today announces the opening of its second office in the APAC region – and eighth office globally – located in the thriving creative hub of Singapore. The move comes as the agency, which made its foray into the APAC region in October 2017 with launch of an office in Sydney, Australia, secures global contracts with a number of both new and existing clients. In the last 12 months, INVNT has achieved a 70% client retention rating and worked with 23 new clients worldwide. "The global demand for live events is continually on the rise, with more and more organizations elevating “live” as a core part of their marketing, sales and public relations strategies. At INVNT we believe in the power of live brand storytelling™, as it enables our clients to create deeper, more meaningful relationships with their target audiences,” said Scott Cullather, CEO, INVNT. "With businesses benefitting from the posi

INVNT Expands Global Footprint With Singapore Launch21.1.2019 15:06Pressemelding

NEW YORK, NY, Jan. 21, 2019 (GLOBE NEWSWIRE) -- INVNT, the global live brand storytelling agency™, today announces the opening of its second office in the APAC region – and eighth office globally – located in the thriving creative hub of Singapore. The move comes as the agency, which made its foray into the APAC region in October 2017 with launch of an office in Sydney, Australia, secures global contracts with a number of both new and existing clients. In the last 12 months, INVNT has achieved a 70% client retention rating and worked with 23 new clients worldwide. "The global demand for live events is continually on the rise, with more and more organizations elevating “live” as a core part of their marketing, sales and public relations strategies. At INVNT we believe in the power of live brand storytelling™, as it enables our clients to create deeper, more meaningful relationships with their target audiences,” said Scott Cullather, CEO, INVNT. "With businesses benefitting from the posi

Tenaris completes acquisition of significant stake in Saudi Steel Pipe Company21.1.2019 13:57Pressemelding

LUXEMBOURG, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE, Buenos Aires and Mexico: TS and MTA Italy: TEN) announced today that it closed its previously-announced acquisition from a private group of 47.79% of the shares of Saudi Steel Pipe Company (“SSP”), a welded steel pipes producer listed on the Saudi stock market, for a total amount of SAR 529.8 million (approximately US$141 million). SSP’s facilities are located in the Eastern Province of the Kingdom of Saudi Arabia and have a manufacturing capacity of 360,000 tons per year. The company, which started its operations in 1980 and serves energy, industrial and commercial segments, is qualified to supply products with major national oil companies in the region, including Saudi Aramco. Upon the closing of the transaction, four Tenaris’s nominees were appointed as new members of SSP’s board of directors. In addition, SSP’s board of directors appointed Mariano Armengol, a senior executive with Tenaris, as managing director and ch

FocusCura subsidiary Luscii will continue as independent company with partner OMRON Healthcare to accelerate their international expansion21.1.2019 12:37Pressemelding

Joining forces supports hospitals in moving care towards the home AMSTERDAM, The Netherlands, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Luscii, the e-health application for remote monitoring developed by FocusCura, is set to continue as an independent company. Healthcare entrepreneur and FocusCura founder Daan Dohmen has acquired the majority of the shares and formed a strategic partnership with OMRON Healthcare, known among other things as the largest manufacturer of blood pressure monitors in the world. Part of this cooperation includes an investment, with which Luscii can accelerate its development further in the coming years. OMRON will also support launches in more European countries, as the two companies announced today. Remote monitoring With Luscii, chronically ill patients can be monitored remotely. Remote monitoring via the Luscii app, in combination with smart algorithms, warns the patient's healthcare network in the event of a deteriorating health situation. Direct contact is then